Fabio A B Schutz1, Wanling Xie1, Frede Donskov2, Monica Sircar3, David F McDermott4, Brian I Rini5, Neeraj Agarwal6, Sumanta Kumar Pal7, Sandy Srinivas8, Christian Kollmannsberger9, Scott A North10, Lori A Wood11, Ulka Vaishampayan12, Min-Han Tan13, Mary J Mackenzie14, Jae Lyun Lee15, Sun-Young Rha16, Takeshi Yuasa17, Daniel Y C Heng18, Toni K Choueiri19. 1. Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. 2. Aarhus University Hospital, Aarhus, Denmark. 3. Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA. 4. Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. 5. Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH, USA. 6. Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA. 7. City of Hope Comprehensive Cancer Center, Duarte, CA, USA. 8. Stanford Medical Center, Stanford, CA, USA. 9. British Columbia Cancer Agency, Vancouver, BC, Canada. 10. Cross Cancer Institute, Edmonton, AB, Canada. 11. Dalhousie University, Halifax, NS, Canada. 12. Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA. 13. National Cancer Centre Singapore, Singapore. 14. London Regional Cancer Program, London, ON, Canada. 15. Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. 16. Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea. 17. Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan. 18. Tom Baker Cancer Center, Calgary, AB, Canada. 19. Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: toni_choueiri@dfci.harvard.edu.
Abstract
BACKGROUND: Hyponatremia has been associated with poor survival in many solid tumors and more recently found to be of prognostic and predictive value in metastatic renal cell cancer (mRCC) patients treated with immunotherapy. OBJECTIVE: To investigate the influence of baseline hyponatremia in mRCC patients treated with targeted therapy in the International Metastatic Renal Cell Carcinoma Database Consortium. DESIGN, SETTING, AND PARTICIPANTS: Data on 1661 patients treated with first-line vascular endothelial growth factor (VEGF) or mammalian target of rapamycin (mTOR) targeted therapy for mRCC were available from 18 cancer centers to study the impact of hyponatremia (serum sodium level <135 mmol/l) on clinical outcomes. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary objective was overall survival (OS) and secondary end points included time to treatment failure (TTF) and the disease control rate (DCR). The chi-square test was used to compare the DCR in patients with and without hyponatremia. OS and TTF were estimated with the Kaplan-Meier method and differences between groups were examined by the log-rank test. Multivariable logistic regression (for DCR) and Cox regression (for OS and TTF) were undertaken adjusted for prognostic risk factors. RESULTS AND LIMITATIONS: Median OS after treatment initiation was 18.5 mo (95% confidence interval [CI], 17.5-19.8 mo), with 552 (33.2%) of patients remaining alive on a median follow-up of 22.1 mo. Median baseline serum sodium was 138 mmol/l (range: 122-159 mmol/l), and hyponatremia was found in 14.6% of patients. On univariate analysis, hyponatremia was associated with shorter OS (7.0 vs 20.9 mo), shorter TTF (2.9 vs 7.4 mo), and lower DCR rate (54.9% vs 78.8%) (p<0.0001 for all comparisons). In multivariate analysis, these effects remain significant (hazard ratios: 1.51 [95% CI, 1.26-1.80] for OS, and 1.57 [95% CI, 1.34-1.83] for TTF; odds ratio: 0.50 [95% CI, 34-0.72] for DCR; adjusted p<0.001). Results were similar if sodium was analyzed as a continuous variable (adjusted p<0.0001 for OS, TTF, and DCR). CONCLUSIONS: This is the largest multi-institutional report to show that hyponatremia is independently associated with a worse outcome in mRCC patients treated with VEGF- and mTOR-targeted agents.
BACKGROUND:Hyponatremia has been associated with poor survival in many solid tumors and more recently found to be of prognostic and predictive value in metastatic renal cell cancer (mRCC) patients treated with immunotherapy. OBJECTIVE: To investigate the influence of baseline hyponatremia in mRCC patients treated with targeted therapy in the International Metastatic Renal Cell Carcinoma Database Consortium. DESIGN, SETTING, AND PARTICIPANTS: Data on 1661 patients treated with first-line vascular endothelial growth factor (VEGF) or mammalian target of rapamycin (mTOR) targeted therapy for mRCC were available from 18 cancer centers to study the impact of hyponatremia (serum sodium level <135 mmol/l) on clinical outcomes. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary objective was overall survival (OS) and secondary end points included time to treatment failure (TTF) and the disease control rate (DCR). The chi-square test was used to compare the DCR in patients with and without hyponatremia. OS and TTF were estimated with the Kaplan-Meier method and differences between groups were examined by the log-rank test. Multivariable logistic regression (for DCR) and Cox regression (for OS and TTF) were undertaken adjusted for prognostic risk factors. RESULTS AND LIMITATIONS: Median OS after treatment initiation was 18.5 mo (95% confidence interval [CI], 17.5-19.8 mo), with 552 (33.2%) of patients remaining alive on a median follow-up of 22.1 mo. Median baseline serum sodium was 138 mmol/l (range: 122-159 mmol/l), and hyponatremia was found in 14.6% of patients. On univariate analysis, hyponatremia was associated with shorter OS (7.0 vs 20.9 mo), shorter TTF (2.9 vs 7.4 mo), and lower DCR rate (54.9% vs 78.8%) (p<0.0001 for all comparisons). In multivariate analysis, these effects remain significant (hazard ratios: 1.51 [95% CI, 1.26-1.80] for OS, and 1.57 [95% CI, 1.34-1.83] for TTF; odds ratio: 0.50 [95% CI, 34-0.72] for DCR; adjusted p<0.001). Results were similar if sodium was analyzed as a continuous variable (adjusted p<0.0001 for OS, TTF, and DCR). CONCLUSIONS: This is the largest multi-institutional report to show that hyponatremia is independently associated with a worse outcome in mRCC patients treated with VEGF- and mTOR-targeted agents.
Authors: Mihai Gheorghiade; Joseph S Rossi; William Cotts; David D Shin; Anne S Hellkamp; Ileana L Piña; Gregg C Fonarow; Teresa DeMarco; Daniel F Pauly; Joseph Rogers; Thomas G DiSalvo; Javed Butler; Joshua M Hare; Gary S Francis; Wendy Gattis Stough; Christopher M O'Connor Journal: Arch Intern Med Date: 2007-10-08
Authors: Daniel Y C Heng; Wanling Xie; Meredith M Regan; Mark A Warren; Ali Reza Golshayan; Chakshu Sahi; Bernhard J Eigl; J Dean Ruether; Tina Cheng; Scott North; Peter Venner; Jennifer J Knox; Kim N Chi; Christian Kollmannsberger; David F McDermott; William K Oh; Michael B Atkins; Ronald M Bukowski; Brian I Rini; Toni K Choueiri Journal: J Clin Oncol Date: 2009-10-13 Impact factor: 44.544
Authors: A Ginès; A Escorsell; P Ginès; J Saló; W Jiménez; L Inglada; M Navasa; J Clària; A Rimola; V Arroyo Journal: Gastroenterology Date: 1993-07 Impact factor: 22.682
Authors: R Berardi; M Caramanti; I Fiordoliva; F Morgese; A Savini; S Rinaldi; M Torniai; M Tiberi; C Ferrini; M Castagnani; F Rovinelli; A Onofri; S Cascinu Journal: Support Care Cancer Date: 2014-08-21 Impact factor: 3.603
Authors: R Berardi; M Caramanti; M Castagnani; S Guglielmi; F Marcucci; A Savini; F Morgese; S Rinaldi; C Ferrini; M Tiberi; M Torniai; F Rovinelli; I Fiordoliva; A Onofri; S Cascinu Journal: Support Care Cancer Date: 2015-03-05 Impact factor: 3.603
Authors: Katrin Hefler-Frischmuth; Christoph Grimm; Lisa Gensthaler; Elisabeth Reiser; Richard Schwameis; Lukas A Hefler Journal: Wien Klin Wochenschr Date: 2018-09-03 Impact factor: 1.704
Authors: Oliver D Mrowczynski; Alexandre J Bourcier; Jason Liao; Sara T Langan; Charles S Specht; Elias B Rizk Journal: J Neurooncol Date: 2018-01-25 Impact factor: 4.130
Authors: Scott M Haake; Samira A Brooks; Eric Welsh; William J Fulp; Dung-Tsa Chen; Jasreman Dhillon; Eric Haura; Wade Sexton; Philippe E Spiess; Julio Pow-Sang; W Kimryn Rathmell; Mayer Fishman Journal: Urol Oncol Date: 2015-11-03 Impact factor: 3.498
Authors: Fernando Henao; Aranzazu Manzano; Rafael Lopez Lopez; Ana Luisa Gobartt; Ramón de Las Peñas Journal: Adv Ther Date: 2020-10-27 Impact factor: 3.845